Skip to main content
. Author manuscript; available in PMC: 2018 Nov 29.
Published in final edited form as: Ann Oncol. 2018 Jan 1;29(1):145–153. doi: 10.1093/annonc/mdx483

Figure 2.

Figure 2

Evolution of ESR1 mutations during aromatase inhibitor (AI) therapy. (A–D) Mutation tracking in ctDNA collected during first line AI therapy. Data from four patients with ESR1 subclonal mutations detectable in ctDNA tracked until clinical progression. Allele fractions are shown as determined by sequencing. TP53 mutation in grey likely to have arisen from Clonal Haematopoesis of Indeterminate Potential (CHIP). (E) Percentage of cases with monoclonal (59.1%) or polyclonal ESR1 mutations (40.9%).